Giora Fishman hired as VP Commercialization, USA

RenalSense welcomes Giora Fishman to the team as VP Commercialization, USA. Giora is a seasoned business executive, with diverse experience in Business Development, Operations, and Sales. Prior to joining RenalSense he held senior management positions, primarily in the Healthcare Industry in the US and in Israel, with companies such as Baxter International, Bristol Myers Squibb, Datascope, and Mennen Medical.

Michael Boxman joins as VP Sales & Marketing, Europe

RenalSense welcomes Michael Boxman as VP Sales & Marketing, Europe. Michael has 15 years’ experience in medical device sales and business development in the EU and has a deep understanding of the healthcare sector in the different European countries. Previously he was director of business development EMEA at Eight Medical International. Michael holds an MBA from a Dutch business school.

RenalSense joins the Patient Safety Movement Foundation’s “Commit to ZERO” Program

RenalSense has joined the Patient Safety Movement Foundation (PSMF) in making a commitment to ZERO patient harm and death, in line with our goal of reducing morbidity and mortality due to kidney injury. The PSMF is a global nonprofit organization, building a global database of organizations who are committed to eliminating preventable patient harm and death. For more information on the PSMF click here.

Adam Goldberger joins as Chief Business Officer

RenalSense welcomes Adam Goldberger as Chief Business Officer. Most recently, Adam was a Group Executive for a leading private equity-backed Australian health risk management platform company which grew exponentially utilizing a multi-brand, multi-channel approach to market. He has led entrepreneurial companies through significant growth phases and driven change management agendas through innovation and adoption of best practice.

Yishai Klein joins the Board of Directors

RenalSense welcomes Yishai Klein to its Board of Directors. Yishai Klein is the Managing Partner and Co-Founder of Singapore-based venture firm, BlueRed PartnersPrior to forming BlueRed, Yishai served as both Advisor and Head of Innovation and Strategic Investments at the OUE group.  Formerly, Yishai was Head of Asia at Giza Venture Capital. He currently serves on the boards of Cynet, Gauzy, DouxMatok, Optibus, Panorays and EarlySense.

RenalSense raises $14M Series A Funding to Bolster Global Commercialization and Expand its Product Line

RenalSense secured $14M to bolster global commercialization of the Clarity RMS, expand clinical validation to additional clinical settings, and advance the release of its next generation products based on its sensor platform. The Series A round was led by BlueRed Partners Fund (Singapore) and includes several large healthcare-focused family offices as well as existing shareholders. See Press Release.

RenalSense Announces Distribution Agreement in Taiwan with Pacific Hospital Supply Co. (PAHSCO)

RenalSense has signed a distribution agreement in Taiwan with Pacific Hospital Supply Co. (PAHSCO), an industry leader of disposable medical supplies and equipment. PAHSCO will market RenalSense’s Clarity RMS™ critical care monitoring system to hospitals throughout Taiwan.

RenalSense Announces Distribution Agreement in Mainland China with Gloryway

RenalSense™ has signed a distribution agreement for mainland China with Gloryway, a leading distributor of medical devices. Gloryway will market and manufacture the Clarity RMS™ to hospitals throughout mainland China. See Press Release.

Medline, RenalSense Partner to Offer UO Monitoring System

RenalSense has entered into a distribution agreement for North America with Medline, the largest privately held manufacturer and distributor of medical supplies. See Press Release.

RenalSense Announces Distribution Agreement in Israel with Medtechnica

RenalSense has signed a distribution agreement with Medtechnica, Israel’s largest distributor of medical equipment and health services. Medtechnica will market RenalSense’s Clarity RMS™ critical care monitoring system to hospitals throughout Israel. See Press Release.

RenalSense launches clinical trial at New York’s Columbia University

RenalSense recently launched a study at Columbia University Irving Medical Center in New York under the direction of Professor Gebhard Wagener of the Department of Anesthesiology. In this study of 100 adult patients, continuous urine flow will be measured before, during, and after cardiac surgery in order to evaluate its ability to detect renal injury, assessed by the incidence of AKI and by post-operative measurements of NGAL, a urinary biomarker.

RenalSense Announces Partnership with CHF Solutions

RenalSense has entered into a partnership agreement with CHF Solutions in the United States to offer complementary solutions for fluid management. CHF Solutions will market and sell RenalSense’s Clarity RMS™ (real-time monitoring system) in certain U.S. territories.  For more details see Press Release.

RenalSense releases two articles in ICU Management & Practice

RenalSense recently released two articles in the periodical ICU Management & Practice, in a special issue dedicated to COVID-19. The first article, entitled “Continuous Monitoring of Urine Flow in COVID-19 and Other Critical Care Patients: Why and How” appeared in the online and print versions of the Journal. The second article, entitled “COVID-19 and Acute Kidney Injury” appeared in the weekly newsletter dedicated to the same topic.

Clarity RMS installed in Israel’s largest private hospital chain

Installations of the Clarity RMS are on the rise also in Israel in the COVID-19 era. The latest site, Assuta Ashdod, is a branch of Israel’s largest private chain of medical centers, where the systems are being used for patients in the general ICU, including isolated cases of COVID-19.

RenalSense starts delivery of its first orders of Clarity RMS in Europe

RenalSense has started commercial sales of its Clarity RMS™ system in Europe in conjunction with its distribution partner Fresenius Medical Care (Bad Homburg). The Clarity RMS received CE Mark approval in August 2019. See Press Release.

RenalSense obtains CE Mark for Clarity RMS

RenalSense has obtained CE Mark approval for its Clarity RMS™ system for real-time monitoring of urine flow in the critical care and peri-operative setting. The CE Mark approval allows the company to commercialize its technology in the European Union (EU), where Fresenius Medical Care (Bad Homburg) is its distribution partner. See Press Release.

RenalSense awarded 3 million NIS grant for medical innovation

RenalSense is one of three Israeli medtech companies that were recently awarded funding grants from the Israel Innovation Authority and the Israeli Ministry of Economy and Industry. The company received 3 million NIS for development of its second generation system.

RenalSense to present at MedCity INVEST

RenalSense will be making a presentation at the “Pitch Perfect Startup Contest” at MedCity INVEST, to be held April 23-24 in Chicago. MedCity INVEST is a leading national healthcare investing conference uniting active investors with corporate business development executives to facilitate investment opportunities with the most promising healthcare startups.

RenalSense sponsors industry symposium at AKI&CRRT 2019 meeting

As part of the 2019 AKI&CRRT meeting in San Diego, RenalSense sponsored a symposium entitled “Urine Flow Rate and its Use as a Biomarker in Critical Care.” The speakers were Professor John Kellum, Director of the Center for Critical Care Nephrology at the University of Pittsburgh, and Professor Robert Safirstein of the Department of Medicine (Nephrology) at Yale University. The presentations covered the potential of urine flow as an early indicator of AKI, and as a real-time parameter for response to therapy, and for local and systemic disease. Watch video of Kellum lecture.

RenalSense participates in Israeli industry delegation to China

In mid-December, RenalSense participated in an Israeli industry delegation to China, consisting of 26 companies selected by the China-Israel Joint Committee on Innovation Cooperation. As a member of the delegation, we conducted a speaking tour in Changzhou, Shenzhen, Shanghai and Beijing, to promote joint innovation and collaboration between the two countries.

Renalsense announces pilot study at University of Pittsburgh Medical Center

RenalSense® announced today that it is conducting a pilot study with its Clarity RMS® critical care monitoring system at the University of Pittsburgh Medical Center (UPMC), under the direction of Professor John Kellum. See Press Release.

RenalSense to represent Israel at International Entrepreneurship Competition in China

RenalSense is proud to announce that it was selected as one of five companies to represent Israel at the Xi’an International Entrepreneurship Competition for outstanding global innovation this December. The competition, sponsored by the Xi’an Municipal Government, includes startups in the fields of IT, bio-med, advanced manufacturing and new materials from Silicon Valley, Berlin, London, Brisbane, and Tel Aviv, as well as from six regions in China.

RenalSense Announces Distribution Agreement With Fresenius Medical Care

RenalSense® has entered into an agreement with Fresenius Medical Care (Bad Homburg) for distribution of its Clarity RMS critical care urine monitoring system in Europe, the Middle East, and Africa (EMEA). Fresenius Medical Care will market the company’s products in 85 EMEA countries through its acute care division. See Press Release.

RenalSense to present at ASN Kidney Week 2017

RenalSense will be participating in the upcoming ASN Kidney Week 2017 Annual Meeting, to be held Oct 31st – Nov 5th in New Orleans.

​The company will present a scientific poster entitled “Identification of the Oliguric Patient Using a Novel Electronic Device for Measuring Urine Output” on Thursday Nov 2nd in the 10:00 am Poster Session on AKI. The company will also ​be exhibiting at ​Booth ​#514, where visitors will have the opportunity to meet with members of the senior management team.

RenalSense publishes scientific paper

RenalSense published its first full-length article in the September issue of “Clinical Medicine Insights: Trauma and Intensive Medicine”. 

The article describes the company’s recent clinical trial conducted in the ICU at Jerusalem’s Hadassah Hospital.

RenalSense installs Clarity RMS at Mt. Sinai in NY

RenalSense installed its first Clarity RMS Urine Monitoring System in the surgical ICU at New York’s Mt. Sinai West (formerly Roosevelt Hospital), under the supervision of Professor Hassan Khouli.

RenalSense to present at AKI&CRRT 2017

RenalSense will be participating in the upcoming AKI&CRRT 2017 – The 22 nd International Conference on Advances in Critical Care Nephrology – Updates in ICU Medicine: Controversies, Challenges, and Solutions, to be held March 7th-10th in San Diego.

Dr. Mor Grinstein, Co-Founder and Chief Medical Officer, will be making an oral presentation entitled “A Novel Electronic Device for Measuring Urine Flow Rate” on Wednesday March 8 th in the 6:00 PM session on Clinical Research in AKI and NAP.

The company will also have an exhibition booth at the conference, where visitors will have the opportunity to meet with members of the senior management team.

RenalSense selected to present to Biomed Investors Group

RenalSense was selected as one of five companies to present at the JLM-Biocity Biomed Startup Pitch Evening held on December 20th in Jerusalem.  JLM-Biocity is a private initiative of 900 bio entrepreneurs, professionals and businesspeople seeking to make Jerusalem a global life science innovation leader. The presentation was made to a panel of investors, VC funds, and global companies.

RenalSense presents clinical data at Annual ASN Congress

RenalSense’s clinical team presented a scientific poster at Kidney Week of the American Society of Nephrology (ASN) 2016 in Chicago. The poster summarized the findings of the company’s recent prospective trial with 40 ICU patients at Hadassah Hospital in Jerusalem, Israel. See the abstract.